1,336 research outputs found
Abstract 1397: Antisense oligo nucleotide of Annexin A4 improved platinum resistance in ovarian clear cell cancer
No full textAbstract
Introduction: Ovarian cancer in Japan are classified as clear cell carcinoma (CCC) more than 20 %, this percentage is higher than in Europe and United States. Besides, it is well known that CCC of ovary is highly resistant to cancer chemotherapy including carboplatin and paclitaxel treatment. We reported that Annexin A4 protein was overexpressed in ovarian CCC tissues by immunohistochemical analysis. Elevated Annexin A4 level has been detected in various epithelial cancer cell lines and have reported associating with chemoresistance to platinum-based cancer drugs. To overcome the platinum chemoresistance, we thought antisense oligonucleotides (ASOs) to be a good therapeutic option in a way of highly specific therapy for improving chemoresistance by suppressing the expression of Annexin A4 in cancer cells.
Methods: We generated ASO targeting Annexin A4 with 2’, 4’-bridged nucleic acid. And we analyzed suppression of Annexin A4 in ASO-transfected RMG-I cell line (CCC) in vitro using real time PCR and western blotting. In 16 types of ASOs targeting Annexin A4, 2 ASOs were eligible. Cells were seeded in 96-well plates (2,000 cells per well). Next day, cells were transfected with ASOs using lipofectamine 2000 and were exposed to various concentrations of cisplatin (0 - 100 μM) for 72 hr. Then, drug concentrations resulting in a 50% inhibition of cell growth (IC50 values) were calculated. Intracellular platinum accumulation in Annexin A4 overexpressing cells was analyzed. To assess the improvement of platinum resistance in vivo, we used ICR nu/nu mice xenografted subcutaneously with RMG-I cells. Intraperitoneal injection of cisplatin 3mg/kg after intratumoral administration of ASO 1mg/kg each twice a week were given to xenograft mice.
Results: By realtime PCR analysis, among strong 16 types of ASOs targeting Annexin A4, 2 ASOs showed strong knockdown efficiency (about 80% knockdown) compared to negative control ASOs. Western blotting analysis showing knockdown of Annexin A4 expression was observed in Annexin A4 ASO transfected cells compared to no treatment or control ASOs in vitro. ASO-transfected RMG-I cells was less resistant to cisplatin (IC50 = 3.3μM) compared with control cells (IC50 = 5.2μM) Same result were obtained with carboplatin. Platinum resistance was significantly improved in treated with Annexin A4 ASO and cisplatin compared to control ASO and cisplatin treated group in vivo.
Conclusion: By transfection of ASOs targeting Annexin A4, platinum resistance have improved in vivo and in vitro, Annexin A4 have associated with efflux of platinum anti-tumor drug. In conclusion, antisense oligonucleotides for Annexin A4 will be a therapeutic option for ovarian clear cell carcinoma with chemoresistance to platinum antitumor drug.
Citation Format: Reisa Kakubari, Satoshi Nakagawa, Tadashi Iwamiya, Eiji Kobayashi, Shinnya Matsuzaki, Yutaka Ueda, Kiyoshi Yoshino, Yuya Kasahara, Satoshi Obika, Tadashi Kimura, Satoshi Serada, Tetsuji Naka, Minoru Fujimoto. Antisense oligo nucleotide of Annexin A4 improved platinum resistance in ovarian clear cell cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1397. doi:10.1158/1538-7445.AM2017-1397</jats:p
A successful model of regional healthcare information exchange in Japan: Case Study in Kagawa Prefecture
No full textIn this study, we focused on analysis of healthcare data exchange over the network. For the advance of broadband capability development, many governments expect online medical information exchange between medical institutions. Japanese government also has tried to deploy ICT in the healthcare field. In Japan, many healthcare ICT projects started, but almost of all the projects face many issues and failed to continue. This situation caused us to clarify the success factor of healthcare information exchange network. For inspecting the success factors, we analyzed information access of healthcare systems in Kagawa prefecture of Japan. Kagawa prefecture is one of the most advance areas for healthcare information technology. We analyzed four medical ICT projects in Kagawa prefecture: K-MIX, Critical Pathway for Diabetes, E-prescription, and PHR. In addition, we inspected characteristics of exchanged data in the network, and stakeholder involved in these projects. This analysis lets us find various types of healthcare ICT projects. Characteristic of data processed in the projects caused differences of characteristic of the projects. On the other hand, multiple systems process same data, though the project does not share the data itself. Considering various types of medical information exchanges projects, we propose classification and standard format of exchanged data according to their characteristic are critical for efficient business deployment. --e-Health,regional healthcare information exchange,EHR
Analysis for science librarians of the 2015 Nobel Prize in Physiology or Medicine: the life and work of William C. Campbell, Satoshi Ōmura, and Youyou Tu
No full textParasites affect humans worldwide with varying degrees of seriousness. Some of the most impactful parasitic infections affect millions of people, many of whom are already impoverished and struggling. The discoveries of the 2015 Nobel Laureates in Physiology of Medicine have changed the way some of these serious parasitic infections are treated, saving and improving the lives of countless people. These Laureates are William C. Campbell, Satoshi Ōmura, and Youyou Tu
Adelencyrtus odonaspidis Fullaway 1913
No full textAdelencyrtus odonaspidis Fullaway, 1913 Comments. The Japanese record is based on BURKS (1958), but this author did not state which material was examined or where the information originated.Published as part of Japoshvili, George, Higashiura, Yoshimitsu & Kamitani, Satoshi, 2016, A review of Japanese Encyrtidae (Hymenoptera), with descriptions of new species, new records and comments on the types described by Japanese authors, pp. 345-401 in Acta Entomologica Musei Nationalis Pragae 56 (1) on page 395, DOI: 10.5281/zenodo.530683
Screening for Novel Serum Biomarker for Monitoring Disease Activity in Rheumatoid Arthritis Using iTRAQ Technology-Based Quantitative Proteomic Approach
No full textAPHERP symposium session III : Higher education graduate employment for uncertain futures
No full textPresented Titles: What Can We Learn from the Past Crisis and Uncertainty? Re-examining the Impact of Global Financial Crisis on Graduate Employment in Japan [Author: Satoshi Araki] A Critical Review of Skills that Higher Education should Prepare Students for the Era of Fourth Industrial Revolution [Authors: Weiyan Xiong; Huiyuan Ye] Evaluating Intention to Migrate to the Greater Bay Cities in Mainland China: A Multi-Group Analysis among Hong Kong Adults [Authors: Joshua Ka-ho Mok; Alex Zhu; Genghua Huang] Unpacking Rising Degree Requirements in the British Labour Market [Authors: Golo Henseke; Alan Felstead; Duncan Gallie; Francis Green
Donner de la voix aux mythes (extrait) : Satoshi Miyagi ou la dramaturgie des ombres: Donner de la voix aux mythes (extrait) : Satoshi Miyagi ou la dramaturgie des ombres
No full textInternational audienceDirector Satoshi Miyagi made a name in France with his staging of Mahabaratha, created in 2006 for the inauguration of the Claude Lévi-Strauss Theater at the Musée du Quai Branly in Paris and then programmed at the Festival d'Avignon in 2014 in the carrière Boulbon. The Musée du Quai Branly invited him back in 2016 for a creation specially conceived for the Théâtre Claude Lévi-Strauss, to mark the museum's 10th anniversary: Le lièvre blanc d'Inaba et des Navajos (The White Hare of Inaba and the Navajo), a cross between anthropological writings on Amerindian myths and their universality by Claude Lévi-Strauss and traditional Japanese tales. He returned to the Festival d'Avignon, at the invitation of Olivier Py, with a masterful and memorable performance of Sophocles' Antigone in the courtyard of the Palais des Papes in 2017. Invited by Wajdi Mouawad to the Théâtre de la Colline in Paris in 2018, he created Révélation Red in blue trilogy by Léonora Miano, a French-Cameroonian author. Then in March 2022, he returns to the Musée du Quai Branly with the epic of Gilgamesh. He follows this up with Mozart's opera seria Idomeneo, Re di Creta at the Festival d'Aix-en-Provence. Idomeneo is his first work for opera in Europe, followed by Mitridate Re di Ponto, another Mozart opera seria re-presented in December 2022 at Berlin's Staatsoper Unter den Linden.His theater conjures up a dramaturgy of shadows and spirits, whether earthly (wandering souls, ancestors) or from nature, in a holistic animist perspective specific to Japanese culture and its various communities. Indeed, for him, "Acting, whatever the piece, means summoning the absent - usually the dead - to return to us. (...) The shows we create are intended precisely to dialogue with and delight these souls from different parts of the planet and different eras. (...) The actors function as a 'window' enabling the spectators to meet the spirits of the absent." His approach aims to open up the public's perceptions, in a non-anthropocentric, holistic way. In addition to his work as a director, Satoshi Miyagi coordinates the annual Shizuoka International Theatre Festival in Japan, inviting artists from all horizons to present and create shows in a spirit of cultural dialogue.Le metteur en scène Satoshi Miyagi s’est fait connaître en France avec sa mise en scène du Mahabaratha créée en 2006 pour l’inauguration du théâtre Claude Lévi-Strauss au musée du Quai Branly à Paris puis programmé au Festival d’Avignon en 2014 dans la carrière Boulbon. Le musée du Quai Branly l’invite à nouveau en 2016 pour une création spécialement conçue pour le théâtre Claude Lévi-Strauss, à l’occasion des 10 ans du musée : Le lièvre blanc d’Inaba et des Navajos, composée de croisements entre les écrits anthropologiques sur les mythes amérindiens et leur universalité par Claude Lévi-Strauss et les contes traditionnels japonais. Il revient au Festival d’Avignon, à l’invitation d’Olivier Py, avec une magistrale et mémorable Antigone de Sophocle dans la cour du Palais des Papes en 2017. Invité par Wajdi Mouawad au Théâtre de la Colline à Paris en 2018, il crée Révélation Red in blue trilogie de Léonora Miano, une autrice franco-camerounaise. Puis en mars 2022, avec l’épopée de Gil-gamesh, il revient au musée du Quai Branly. Il enchaine avec l’opéra Idomeneo, Re di Creta, un opéra seria de Mozart au Festival d’Aix-en-Provence. Idomeneo constitue le premier tra-vail pour l’opéra en Europe, suivi par Mitridate Re di Ponto, autre opéra seria de Mozart re-présenté en décembre 2022 au Staatsoper Unter den Linden, l’opéra de Berlin.Son théâtre convoque une dramaturgie des ombres, des esprits, qu’ils soient terrestres (âmes errantes, ancêtres) ou issus de la nature dans une perspective animiste holistique propre à la culture japonaise et à ses différentes communautés. En effet, pour lui « Jouer signifie, quelle que soit la pièce, convoquer des absents – des morts, le plus souvent – pour les faire revenir parmi nous. (…) Les spectacles que nous créons sont justement destinés à dialoguer avec ces âmes venues de diverses régions de la planète et de diverses époques, et à les réjouir. (…) Les acteurs fonctionnent comme une « fenêtre » permettant la rencontre entre les spectateurs et les esprits des absents. » Sa démarche souhaite ouvrir les percep-tions du public, dans une approche non anthropocentrique et holistique. Outre son activité de metteur en scène, Satoshi Miyagi coordonne chaque année le festival international de théâtre de Shizuoka au Japon, invitant des artistes de tous horizons à présenter et créer des spectacles dans un esprit de dialogue des cultures
Abstract 4410: LSR promotes ovarian cancer cell growth following the activation of β-oxidation and its antibody inhibits lipid catabolism
No full textAbstract
Ovarian cancer is the most lethal gynecologic malignancy; thus developing new treatment options is urgently required. Molecular targeted therapies for cancers, which are generally more tolerable than widely used cytotoxic agents, have shown highly specific inhibition of target molecules. In this study, we aimed to identify a new ovarian cancer antigen and to develop a novel monoclonal antibody (mAb). Furthermore we evaluated its preclinical efficacy and analyzed the function of its antigen in ovarian cancer.To identify a new ovarian cancer antigen, cell surface membrane proteins of normal ovarian epithelial and ovarian cancer cell lines were analyzed by iTRAQ-based proteomic technology. We identified lipolysis-stimulated lipoprotein receptor (LSR) as the new therapeutic target for ovarian cancer. By the immunohistochemical analysis, significant poor prognosis was observed in high-LSR expression patients with ovarian cancer compared to patients with low-LSR expression by survival assay (p &lt; 0.05). Our newly developed anti-LSR mAb showed significant inhibition of tumor growth in vivo against xenograft model of LSR-positive ovarian cancer cell line and patient derived LSR-positive ovarian cancer tissue (p &lt; 0.05). In LSR-positive ovarian cancer cells, high number and large lipid droplets were observed compared to LSR-negative cells and anti-LSR mAb decreased these droplets. Moreover addition of VLDL to LSR-positive ovarian cancer cells significantly promoted the cell proliferation (p &lt; 0.05) and anti-LSR mAb inhibited that in vitro (p &lt; 0.05). Supporting these data, addition of VLDL to LSR-positive ovarian cancer cells significantly promoted β-oxidation-mediated lipid catabolism (p &lt; 0.05) and anti-LSR mAb also inhibited that (p &lt; 0.05). In addition, this anti-LSR mAb which cross-reacted with mouse LSR did not show any cytotoxicity on normal organs and lipid metabolism in mice. In summary, high expression of LSR in ovarian cancer was the poor prognostic factor. Our newly developed anti-LSR mAb showed significant tumor growth inhibition against not only LSR-positive ovarian cancer cell line but also patient derived LSR-positive ovarian cancer tissue. In LSR-positive ovarian cancer cells, high number and large lipid droplets were observed and LSR promoted cell proliferation following β-oxidation-mediated lipid catabolism. Anti-LSR mAb inhibited these processes. Our preclinical data demonstrated that targeting LSR by mAb is a promising therapy for patients with LSR-positive ovarian cancer.
Citation Format: Kosuke Hiramatsu, Satoshi Serada, Takayuki Enomoto, Takuhei Yokoyama, Yusuke Takahashi, Minoru Fujimoto, Kiyoshi Yoshino, Tadashi Kimura, Tetsuji Naka. LSR promotes ovarian cancer cell growth following the activation of β-oxidation and its antibody inhibits lipid catabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4410. doi:10.1158/1538-7445.AM2017-4410</jats:p
Social system, reproduction of helpers and sperm competition in the cooperatively breeding fishes (Julidochromis spp.) in Lake Tanganyika
No full text
- …
